Evidence map›Paper›PMID 19782055›Full record

ReviewBrain research2010

Dynorphin, stress, and depression.

Allison T Knoll, William A Carlezon

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Brain research, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 286 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
286citing papers in PubMed, 1 pooled it
8.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

286 citing papers in PubMed, 1 synthesis or guideline pooled it, 453 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Evaluation of opioid modulation in major depressive disorder.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2015
    Trial
  4. Trial
  5. Review
  6. Article
  7. Kappa opioid receptor-dependent depressive-like behaviors associated with morphine withdrawal contribute to stress-induced reinstatement of morphine seeking.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026
    Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. Review

226 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Allison T KnollBehavioral Genetics Laboratory, Department of Psychiatry, Harvard Medical School, McLean Hospital, MRC 217, 115 Mill Street, Belmont, MA 02478, USA.
William A Carlezon
Harvard University · USMcLean Hospital · US

Funding

Roles of nuleus accumbens CREB and Kappa function in depressionR01MH063266 · NIMH · MC LEAN HOSPITAL (BELMONT, MA) · PI CARLEZON, WILLIAM A. · 2001 to 2025
$9.1M
kappa-Opioid Receptor Signaling and Fear BehaviorF31MH078473 · NIMH · MCLEAN HOSPITAL · PI KNOLL, ALLISON · 2006 to 2008
$91k
NIMH NIH HHS F31 MH078473NIMH NIH HHS MH063266NIMH NIH HHS MH078473NIMH NIH HHS R01 MH063266
6 · The paper itself

Abstract

Stress is most often associated with aversive states. It rapidly induces the release of hormones and neuropeptides including dynorphin, which activates kappa opioid receptors (KORs) in the central and peripheral nervous systems. In animal models, many aversive effects of stress are mimicked or exacerbated by stimulation of KORs in limbic brain regions. Although KOR signaling during acute stress may increase physical ability (by producing analgesia) and motivation to escape a threat (by producing aversion), prolonged KOR signaling in response to chronic or uncontrollable stress can lead to persistent expression of behavioral signs that are characteristic of human depressive disorders (i.e., "prodepressive-like" signs). Accumulating evidence suggests that KORs contribute to the progressive amplification (sensitization) of stress-induced behaviors that occurs with repeated exposure to stress. Many of the aversive effects of stress are blocked by KOR antagonists, suggesting that these agents may have potential as therapeutics for stress-related conditions such as depression and anxiety disorders. This review summarizes current data on how KOR systems contribute to the acute (rapid), delayed, and cumulative molecular and behavioral effects of stress. We focus on behavioral paradigms that provide insight on interactions between stress and KOR function within each of these temporal categories. Using a simplified model, we consider the time course and mechanism of KOR-mediated effects in stress and suggest future directions that may be useful in determining whether KOR antagonists exert their therapeutic effects by preventing the development of stress-induced behaviors, the expression of stress-induced behaviors, or both.

Indexed as

AnimalsBrainChronic DiseaseComorbidityDepressive DisorderDisease Models, AnimalDynorphinsFearHumansNarcotic AntagonistsReceptors, Opioid, kappaStress, PsychologicalDynorphinsNarcotic AntagonistsReceptors, Opioid, kappa

Identifiers

PMID19782055
PMCPMC2819644
OpenAlexW2029584624

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.